secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001628280-22-029221
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncology Institute Q3 revenue $65M (+24% YoY); cuts FY2022 guidance on slower acquisitions
--------------------------------------------------------------------------------

- Net loss $2.7M ($0.03 basic loss per share); adjusted EBITDA -$7M vs +$0.1M prior year.
- Revenue guidance cut to $245-250M from $270-310M; adjusted EBITDA guidance lowered to -$28M to -$25M.
- Completed $110M strategic investment via senior convertible notes from Deerfield on August 9, 2022.
- Ended Q3 with 100 clinicians (+27% YoY); expanded to 14 markets with three acquisitions and two de novo clinics.
- Workforce reduction and vendor cost-cutting initiated to align cost structure with revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000162828022029221/0001628280-22-029221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000162828022029221/toi-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-029221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer